Loading…
Employees: 626
Size Ningbo Jansen Superconducting Technologies (688805.SS) is a China Health Care company (Medical Specialties) with a market value of $915M, the 2481st largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥36.37 on 6 Nov 2026.
Performance Over six months the shares fell 30.0%, against -14.8% for the median peer and -16.4% for the China market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth Revenue grew 35.6% over the last twelve months (peer median +6.3%); the operating margin is 14.2% (peer median 11.2%).
Valuation It trades at 9.6× enterprise value to sales against a peer median of 3.5× (4th most expensive of 21).
Price implies For today's price to make sense, revenue must grow about 47% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is +30 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.0 points below its cost of capital (12.1% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | n/a | CN¥577M | CN¥425M | CN¥451M | CN¥359M |
| Revenue growth | — | +36% | -6% | +26% | — |
| Gross profit | n/a | CN¥150M | CN¥107M | CN¥110M | CN¥74.6M |
| EBITDA | n/a | CN¥98.7M | CN¥71.5M | CN¥62.1M | CN¥48.6M |
| Net income | n/a | CN¥75.1M | CN¥55.8M | CN¥48.7M | CN¥34.6M |
| Free cash flow | n/a | CN¥20.0M | -CN¥43.8M | CN¥33.1M | -CN¥51.0M |
| Capital expenditure | n/a | CN¥24.0M | CN¥23.2M | CN¥36.7M | CN¥14.3M |
| Total debt | CN¥123M | CN¥78.8M | CN¥76.6M | CN¥105M | CN¥59.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688805.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.9% | -3.7% | 11th highest of 21 |
| 6-month return | -30.0% | -14.8% | 4th lowest of 21 |
| Distance from 52-week high | -49.9% | -36.2% | 6th lowest of 21 |
| Revenue growth (TTM) | +35.6% | +6.3% | 3rd highest of 21 |
| Operating margin | 14.2% | 11.2% | 8th highest of 21 |
| EV / Sales | 9.6× | 3.5× | 4th most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | 47.2% | 5.0% | most demanding of 17 |
| Growth delivered (Del g) | +17.1% | +11.5% | 3rd highest of 17 |
| Hurdle (Req g minus delivered) | +30.1 pp | -5.0 pp | most demanding of 17 |
| ROIC minus cost of capital | -3.0 pp | +3.6 pp | 5th lowest of 21 |
| EV / EBITDA | 55.9× | 8.9× | 2nd most expensive of 11 |
| Net debt / EBITDA | -5.9× | -0.3× | least indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Ningbo Jansen Superconducting Technologies 688805.SS | China | $915M | -30% | +36% | 14% | 9.6× | 47.2% | +17.1% |
| Seegene 096530.KS | South Korea | $915M | +26% | +12% | 13% | 1.6× | -3.4% | -15.9% |
| LifeTech Scientific 1302.HK | Hong Kong | $914M | -18% | +1% | 12% | 4.0× | 13.3% | +15.5% |
| Aidite (Qinhuangdao) Technology 301580.SZ | China | $919M | -20% | +17% | 18% | 4.2× | 19.9% | +23.3% |
| Beijing SDL Technology 002658.SZ | China | $910M | -21% | -13% | 9% | 3.5× | 18.0% | +2.9% |
| Shanghai Runda Medical Technology 603108.SS | China | $909M | -25% | -12% | -2% | 1.9× | 22.2% | -0.2% |
| Mani 7730.T | Japan | $909M | -15% | +10% | 30% | 3.5× | 1.5% | +13.9% |
| Bioventus BVS | United States | $894M | +1% | +4% | 10% | 2.0× | 6.9% | +12.1% |
| Caina Technology 301122.SZ | China | $938M | +60% | +61% | 0% | 10.3× | n/a | n/a |
| Safilo SFL.MI | Italy | $890M | +24% | -4% | 9% | 0.8× | -0.5% | +4.7% |
| Cisen Pharmaceutical 603367.SS | China | $890M | -15% | -6% | 8% | 0.8× | -12.9% | -1.3% |
| Shantou Institute of Ultrasonic Instruments 301602.SZ | China | $944M | -19% | +4% | 30% | 13.5× | 13.1% | +4.6% |
| Shenzhen YHLO Biotech 688575.SS | China | $950M | -20% | +3% | 12% | 3.4× | 3.1% | +12.7% |
| Kuros Biosciences KURN.SW | Switzerland | $953M | +3% | +41% | 6% | 5.6× | n/a | n/a |
| Modern Dental 3600.HK | Hong Kong | $871M | +19% | +12% | 22% | 1.7× | -7.0% | +11.3% |
| Sino Medical Sciences Technology 688108.SS | China | $868M | -35% | +22% | 19% | 9.1× | 31.0% | +9.9% |
| Beijing Hotgen Biotech 688068.SS | China | $966M | -38% | +8% | -94% | 11.7× | n/a | n/a |
| JINS 3046.T | Japan | $865M | -12% | +14% | 10% | 1.2× | -7.2% | +11.7% |
| MedCap MCAP.ST | Sweden | $864M | +6% | +17% | 15% | 3.7× | 2.9% | +20.9% |
| Eckert & Ziegler EUZ.DE | Germany | $969M | -7% | +4% | 25% | 2.5× | 7.2% | +12.1% |
| Xiangyu Medical 688626.SS | China | $969M | -31% | 0% | 4% | 8.0× | n/a | n/a |